The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Staphylococcus aureus—A Known Opponent against Host Defense Mechanisms and Vaccine Development—Do We Still Have a Chance to Win?
Abstract
The main purpose of this review is to present justification for the urgent need to implement specific prophylaxis of invasive Staphylococcus aureus infections. We emphasize the difficulties in achieving this goal due to numerous S. aureus virulence factors important for the process of infection and the remarkable ability of these bacteria to avoid host defense mechanisms. We precede these considerations with a brief overview of the global necessitiy to intensify the use of vaccines against other pathogens as well, particularly in light of an impasse in antibiotic therapy. Finally, we point out global trends in research into modern technologies used in the field of molecular microbiology to develop new vaccines. We focus on the vaccines designed to fight the infections caused by S. aureus, which are often resistant to the majority of available therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MSCRAMM, such as Factor A (Clfa) and protein A, also play fundamental roles in adherence and immune evasion by binding to fibrinogen and host immunoglobulins [84].”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects
Foster, T. J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux007 · Cited by 845
Kourtis, A. P., Hatfield, K., Baggs, J., Mu, Y., See, I., Epson, E., Nadle, J., Kainer, M. A., Dumyati, G., Petit, S., et al. (2019) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6809e1 · Cited by 701 · cited 1×
“aureus bacteremia leads to approximately 20,000 deaths a year in the USA, which accounts for more deaths than those from AIDS, tuberculosis and viral hepatitis combined together [17,18].”
BackgroundClauditz, A., Resch, A., Wieland, K.-P., Peschel, A., & Götz, F. (2006) · Infection and Immunity · doi:10.1128/iai.00204-06 · Cited by 509
Cosgrove, K., Coutts, G., Jonsson, I.-M., Tarkowski, A., Kokai-Kun, J. F., Mond, J. J., & Foster, S. J. (2007) · Journal of Bacteriology · doi:10.1128/jb.01524-06 · Cited by 334
Staphylococcal response to oxidative stress
Gaupp, R., Ledala, N., & Somerville, G. A. (2012) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2012.00033 · Cited by 253
Where does a Staphylococcus aureus vaccine stand?
Fowler, V. G., & Proctor, R. A. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12570 · Cited by 241 · cited 3×
“aureus vaccines showed protective efficacy in preclinical or early clinical trials, none have been approved for use in humans to date [7,104].”
Background
Research works printed but not linked: 110
- Rosini, 2020, Vaccines against antimicrobial resistance, Front. Immunol., 11, 1048, 10.3389/fimmu.2020.01048 · DOI
- Excler, 2021, Supply and delivery of vaccines for global health, Curr. Opin. Immunol., 71, 13, 10.1016/j.coi.2021.03.009 · DOI
- Castro, 2021, A brief review on Group A Streptococcus pathogenesis and vaccine development, R. Soc. Open Sci., 8, 201991, 10.1098/rsos.201991 · DOI
- Ma, 2021, Pertactin-deficient Bordetella pertussis, vaccine-driven evolution, and reemergence of pertussis, Emerg. Infect. Dis., 27, 1561, 10.3201/eid2706.203850 · DOI
- Masomian, M., Ahmad, Z., Gew, L.T., and Poh, C.L. (2020). Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines, 8. · DOI
- Stuart, J.M. (2021). Editorial for the Special Issue: Bacterial meningitis—Epidemiology and vaccination. Microorganisms, 9. · doi:10.3390/microorganisms9050917
- Teymournejad, 2021, Evasion of immunological memory by S. aureus infection: Implications for vaccine design, Front. Immunol., 12, 633672, 10.3389/fimmu.2021.633672 · DOI · Paper page
- Flouchi, 2021, The relationship between nasal carriage of Staphylococcus aureus and surgical site infections in a Hospital Center in Morocco, Int. J. Microbiol., 2021, 5585588, 10.1155/2021/5585588 · doi:10.1155/2021/5585588
- Lin, J., Peng, Y., Xu, P., Zhang, T., Bai, C., Lin, D., Ou, Q., and Yao, Z. (2016). Methicillin-resistant Staphylococcus aureus nasal colonization in Chinese children: A prevalence meta-analysis and review of influencing factors. PLoS ONE, 11. · doi:10.1371/journal.pone.0159728
- Sakr, 2018, Staphylococcus aureus nasal colonization: An update on mechanisms, epidemiology, risk factors, and subsequent infections, Front. Microbiol., 9, 2419, 10.3389/fmicb.2018.02419 · DOI · Paper page
- Verhoeven, 2014, Detection and clinical relevance of Staphylococcus aureus nasal carriage: An update, Expert Rev. Anti. Infect. Ther., 12, 75, 10.1586/14787210.2014.859985 · DOI
- Dayan, 2016, Staphylococcus aureus: The current state of disease, pathophysiology and strategies for prevention, Expert Rev. Vaccines, 15, 1373, 10.1080/14760584.2016.1179583 · DOI
- Hoerr, 2018, S. aureus endocarditis: Clinical aspects and experimental approaches, Int. J. Med. Microbiol., 308, 640, 10.1016/j.ijmm.2018.02.004 · DOI
- Turner, 2019, Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research, Nat. Rev. Microbiol., 17, 203, 10.1038/s41579-018-0147-4 · DOI · Paper page
- Jensen, 2012, Predictors of mortality in Staphylococcus aureus bacteremia, Clin. Microbiol. Rev., 25, 362, 10.1128/CMR.05022-11 · DOI · Paper page
- Volkow, 2018, Bloodstream infection caused by S. aureus in patients with cancer: A 10-year longitudinal single-center study, Support. Care Cancer, 26, 4057, 10.1007/s00520-018-4275-1 · DOI
- Lu, 2021, Human MALT1 deficiency and predisposition to infections, Curr. Opin. Immunol., 72, 1, 10.1016/j.coi.2021.02.008 · DOI
- Otto, 2018, Staphylococcal biofilms, Microbiol. Spectr., 6, 1, 10.1128/microbiolspec.GPP3-0023-2018 · DOI · Paper page
- Schilcher, K., and Horswill, A.R. (2020). Staphylococcal biofilm development: Structure, regulation, and treatment strategies. Microbiol. Mol. Biol. Rev., 84. · DOI · Paper page
- Zheng, 2018, Colonization of medical devices by staphylococci, Environ. Microbiol., 20, 3141, 10.1111/1462-2920.14129 · DOI · Paper page
- Guo, 2020, Prevalence and therapies of antibiotic-resistance in Staphylococcus aureus, Front. Cell Infect. Microbiol., 10, 107, 10.3389/fcimb.2020.00107 · DOI · Paper page
- Ippolito, 2010, Methicillin-resistant Staphylococcus aureus: The superbug, Int. J. Infect. Dis., 14, S7, 10.1016/j.ijid.2010.05.003 · DOI · Paper page
- Sakamoto, Y., Yamauchi, Y., Jo, T., Michihata, N., Hasegawa, W., Takeshima, H., Matsui, H., Fushimi, K., Yasunaga, H., and Nagase, T. (2021). In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: A matched-pair cohort study. BMC Pulm. Med., 21. · DOI
- Zhen, 2020, Clinical and economic impact of methicillin-resistant Staphylococcus aureus: A multicentre study in China, Sci. Rep., 10, 3900, 10.1038/s41598-020-60825-6 · DOI
- Costerton, 1999, Bacterial biofilms: A common cause of persistent infections, Science, 284, 1318, 10.1126/science.284.5418.1318 · DOI · Paper page
- Flemming, 2016, Biofilms: An emergent form of bacterial life, Nat. Rev. Microbiol., 14, 563, 10.1038/nrmicro.2016.94 · DOI · Paper page
- Costerton, 2004, Bacterial biofilms: From the natural environment to infectious diseases, Nat. Rev. Microbiol., 2, 95, 10.1038/nrmicro821 · DOI · Paper page
- Hall, 2017, Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria, FEMS Microbiol. Rev., 41, 276, 10.1093/femsre/fux010 · DOI · Paper page
- Resch, 2005, Differential gene expression profiling of Staphylococcus aureus cultivated under biofilm and planktonic conditions, Appl. Environ. Microbiol., 71, 2663, 10.1128/AEM.71.5.2663-2676.2005 · DOI · Paper page
- Sadowska, 2013, The immunomodulatory activity of Staphylococcus aureus products derived from biofilm and planktonic cultures, Arch. Immunol. Ther. Exp. (Warsz), 61, 413, 10.1007/s00005-013-0240-3 · DOI
- Bjarnsholt, 2010, Antibiotic resistance of bacterial biofilms, Int. J. Antimicrob. Agents, 35, 322, 10.1016/j.ijantimicag.2009.12.011 · DOI · Paper page
- Stewart, 2002, Mechanisms of antibiotic resistance in bacterial biofilms, Int. J. Med. Microbiol., 292, 107, 10.1078/1438-4221-00196 · DOI · Paper page
- Cheung, 2021, Pathogenicity and virulence of Staphylococcus aureus, Virulence, 12, 547, 10.1080/21505594.2021.1878688 · DOI · Paper page
- 2019, Immune evasion by Staphylococcus aureus, Microbiol. Spectr., 7, 1
- Pietrocola, 2017, Staphylococcus aureus manipulates innate immunity through own and host-expressed proteases, Front. Cell Infect. Microbiol., 7, 166, 10.3389/fcimb.2017.00166 · DOI · Paper page
- Flannagan, 2015, Antimicrobial mechanisms of macrophages and the immune evasion strategies of Staphylococcus aureus, Pathogens, 4, 826, 10.3390/pathogens4040826 · DOI · Paper page
- Shettigar, 2020, Virulence factors and clonal diversity of Staphylococcus aureus in colonization and wound infection with emphasis on diabetic foot infection, Eur. J. Clin. Microbiol. Infect. Dis., 39, 2235, 10.1007/s10096-020-03984-8 · DOI
- Rooijakkers, 2020, Staphylococci evade the innate immune response by disarming neutrophils and forming biofilms, FEBS Lett., 594, 2556, 10.1002/1873-3468.13767 · DOI
- Thammavongsa, 2015, Staphylococcal manipulation of host immune responses, Nat. Rev. Microbiol., 13, 529, 10.1038/nrmicro3521 · DOI · Paper page
- Rooijakkers, 2005, Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases, Nat. Immunol., 6, 920, 10.1038/ni1235 · DOI · Paper page
- Ko, Y.P., Kuipers, A., Freitag, C.M., Jongerius, I., Medina, E., van Rooijen, W.J., Spaan, A.N., van Kessel, K.P., Höök, M., and Rooijakkers, S.H. (2013). Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surface. PLoS Pathog., 9. · DOI
- Kang, 2013, Collagen-binding microbial surface components recognizing adhesive matrix molecule (MSCRAMM) of Gram-positive bacteria inhibit complement activation via the classical pathway, J. Biol. Chem., 288, 20520, 10.1074/jbc.M113.454462 · DOI · Paper page
- Zhang, 2017, Staphylococcus aureus SdrE captures complement factor H’s C-terminus via a novel ‘close, dock, lock and latch’ mechanism for complement evasion, Biochem. J., 474, 1619, 10.1042/BCJ20170085 · DOI · Paper page
- Jusko, 2014, Staphylococcal proteases aid in evasion of the human complement system, J. Innate Immun., 6, 31, 10.1159/000351458 · DOI
- Singh, 2019, Interaction of host and Staphylococcus aureus protease-system regulates virulence and pathogenicity, Med. Microbiol. Immunol., 208, 585, 10.1007/s00430-018-0573-y · DOI
- Guerra, 2017, Epic immune battles of history: Neutrophils vs. Staphylococcus aureus, Front. Cell Infect. Microbiol., 7, 286, 10.3389/fcimb.2017.00286 · DOI · Paper page
- Pidwill, 2021, The role of macrophages in Staphylococcus aureus infection, Front. Immunol., 11, 620339, 10.3389/fimmu.2020.620339 · DOI · Paper page
- Yamada, K.J., Heim, C.E., Xi, X., Attri, K.S., Wang, D., Zhang, W., Singh, P.K., Bronich, T.K., and Kielian, T. (2020). Monocyte metabolic reprogramming promotes pro-inflammatory activity and Staphylococcus aureus biofilm clearance. PLoS Pathog., 16. · DOI
- Mohamed, N., Timofeyeva, Y., Jamrozy, D., Rojas, E., Hao, L., Silmon de Monerri, N.C., Hawkins, J., Singh, G., Cai, B., and Liberator, P. (2019). Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States. PLoS ONE, 14. · DOI
- Nanra, 2013, Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus, Hum. Vaccin. Immunother., 9, 480, 10.4161/hv.23223 · doi:10.4161/hv.23223
- Cheng, A.G., McAdow, M., Kim, H.K., Bae, T., Missiakas, D.M., and Schneewind, O. (2010). Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog., 6. · DOI · Paper page
- Labate, 2018, Staphylococcus aureus clumping factor A is a force-sensitive molecular switch that activates bacterial adhesion, Proc. Natl. Acad. Sci. USA, 115, 5564, 10.1073/pnas.1718104115 · DOI · Paper page
- Tam, 2019, Staphylococcus aureus secreted toxins and extracellular enzymes, Microbiol. Spectr., 7, 2, 10.1128/microbiolspec.GPP3-0039-2018 · DOI · Paper page
- Mandell, 1975, Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro and in vivo studies with emphasis on staphylococcal--leukocyte interaction, J. Clin. Investig., 55, 561, 10.1172/JCI107963 · DOI · Paper page
- Joo, 2015, Mechanisms of resistance to antimicrobial peptides in staphylococci, Biochim. Biophys. Acta., 1848, 3055, 10.1016/j.bbamem.2015.02.009 · DOI
- Flannagan, 2016, Intracellular replication of Staphylococcus aureus in mature phagolysosomes in macrophages precedes host cell death, and bacterial escape and dissemination, Cell Microbiol., 18, 514, 10.1111/cmi.12527 · DOI · Paper page
- Jubrail, 2016, Inability to sustain intraphagolysosomal killing of Staphylococcus aureus predisposes to bacterial persistence in macrophages, Cell Microbiol., 18, 80, 10.1111/cmi.12485 · DOI
- Proctor, 2014, Staphylococcus aureus small colony variants (SCVs): A road map for the metabolic pathways involved in persistent infections, Front. Cell. Infect. Microbiol., 4, 99, 10.3389/fcimb.2014.00099 · DOI · Paper page
- Speziale, 2021, Staphylococcus aureus induces neutrophil extracellular traps (NETs) and neutralizes their bactericidal potential, Comput. Struct. Biotechnol. J., 19, 3451, 10.1016/j.csbj.2021.06.012 · DOI
- Missiakas, 2021, Selective host cell death by Staphylococcus aureus: A strategy for bacterial persistence, Front. Immunol., 11, 621733, 10.3389/fimmu.2020.621733 · DOI
- Berube, 2013, Staphylococcus aureus α-toxin: Nearly a century of intrigue, Toxins, 5, 1140, 10.3390/toxins5061140 · DOI · Paper page
- Daum, 2007, Community-acquired methicillin-resistant Staphylococcus aureus: The role of Panton-Valentine leukocidin, Lab. Investig., 87, 3, 10.1038/labinvest.3700501 · DOI · Paper page
- Darboe, 2019, Prevalence of Panton-Valentine leukocidin (PVL) and antimicrobial resistance in community-acquired clinical Staphylococcus aureus in an urban Gambian hospital: A 11-year period retrospective pilot study, Front. Cell Infect. Microbiol., 9, 170, 10.3389/fcimb.2019.00170 · DOI
- Graves, 2010, Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence, J. Mol. Med., 88, 109, 10.1007/s00109-009-0573-x · DOI
- Cheung, 2014, Phenol-soluble modulins--critical determinants of staphylococcal virulence, FEMS Microbiol. Rev., 38, 698, 10.1111/1574-6976.12057 · DOI · Paper page
- Surewaard, 2013, Staphylococcal alpha-phenol soluble modulins contribute to neutrophil lysis after phagocytosis, Cell Microbiol., 15, 1427, 10.1111/cmi.12130 · DOI · Paper page
- Berlon, 2015, Clinical MRSA isolates from skin and soft tissue infections show increased in vitro production of phenol soluble modulins, J. Infect., 71, 447, 10.1016/j.jinf.2015.06.005 · DOI
- Cruz, 2021, Staphylococcal protein A inhibits complement activation by interfering with IgG hexamer formation, Proc. Natl. Acad. Sci. USA, 118, e2016772118, 10.1073/pnas.2016772118 · DOI
- Deis, 2014, Multiscale conformational heterogeneity in staphylococcal protein A: Possible determinant of functional plasticity, Structure, 22, 1467, 10.1016/j.str.2014.08.014 · DOI
- Pauli, 2014, Staphylococcus aureus infection induces protein A-mediated immune evasion in humans, J. Exp. Med., 211, 2331, 10.1084/jem.20141404 · DOI
- Goodyear, 2003, Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin, J. Exp. Med., 197, 1125, 10.1084/jem.20020552 · DOI · Paper page
- Krakauer, T. (2019). Staphylococcal superantigens: Pyrogenic toxins induce toxic shock. Toxins, 11. · DOI
- Paulsen, J., Mehl, A., Askim, Å., Solligård, E., Åsvold, B.O., and Damås, J.K. (2015). Epidemiology and outcome of Staphylococcus aureus bloodstream infection and sepsis in a Norwegian county 1996-2011: An observational study. BMC Infect. Dis., 15. · DOI
- Tuffs, S.W., Haeryfar, S.M.M., and McCormick, J.K. (2018). Manipulation of innate and adaptive immunity by staphylococcal superantigens. Pathogens, 7. · DOI
- Wójcik-Bojek, U., Rywaniak, J., Bernat, P., Podsędek, A., Kajszczak, D., and Sadowska, B. (2021). An in vitro study of the effect of Viburnum opulus extracts on key processes in the development of staphylococcal infections. Molecules, 26. · DOI
- Zhang, 2018, Master mechanisms of Staphylococcus aureus: Consider its excellent protective mechanisms hindering vaccine development!, Microbiol. Res., 212-213, 59, 10.1016/j.micres.2018.05.002 · DOI
- Nishitani, 2020, IsdB antibody–mediated sepsis following S. aureus surgical site infection, JCI Insight., 5, e141164, 10.1172/jci.insight.141164 · DOI
- Gurtman, 2019, The development of a Staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery, Hum. Vaccin. Immunother., 15, 358, 10.1080/21645515.2018.1523093 · DOI
- Mbaeyi, 2020, Meningococcal vaccination: Recommendations of the advisory committee on immunization practices, United States, 2020, MMWR Recomm. Rep., 69, 1, 10.15585/mmwr.rr6909a1 · DOI · Paper page
- Principi, N., and Esposito, S. (2016). Prevention of community-acquired pneumonia with available pneumococcal vaccines. Int. J. Mol. Sci., 18. · DOI
- Frenck, 2017, Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study, Vaccine, 35, 375, 10.1016/j.vaccine.2016.11.010 · DOI
- Nissen, 2015, A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults, Vaccine, 33, 1846, 10.1016/j.vaccine.2015.02.024 · DOI
- Creech, 2020, Persistence of immune responses through 36 months in healthy adults after vaccination with a novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag), Open Forum Inf. Dis., 7, 1
- Handke, L.D., Gribenko, A.V., Timofeyeva, Y., Scully, I.L., and Anderson, A.S. (2018). MntC-dependent manganese transport is essential for Staphylococcus aureus oxidative stress resistance and virulence. mSphere, 3. · DOI
- Miller, 2020, Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms, FEMS Microbiol. Rev., 44, 123, 10.1093/femsre/fuz030 · DOI · Paper page
- Venkatasubramaniam, 2021, Safety and immunogenicity of a 4-component toxoid-based Staphylococcus aureus vaccine in rhesus macaques, Front. Immunol., 12, 621754, 10.3389/fimmu.2021.621754 · DOI
- Raafat, 2019, Fighting Staphylococcus aureus biofilms with monoclonal antibodies, Trends Microbiol., 27, 303, 10.1016/j.tim.2018.12.009 · DOI
- Rupp, 2007, Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia, Antimicrob. Agents Chemother., 51, 4249, 10.1128/AAC.00570-07 · DOI
- Yu, X.Q., Robbie, G.J., Wu, Y., Esser, M.T., Jensen, K., Schwartz, H.I., Bellamy, T., Hernandez-Illas, M., and Jafri, H.S. (2016). Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob. Agents Chemother., 61. · DOI
- Chan, L.C., Chaili, S., Filler, S.G., Miller, L.S., Solis, N.V., Wang, H., Johnson, C.W., Lee, H.K., Diaz, L.F., and Yeaman, M.R. (2017). Innate immune memory contributes to host defense against recurrent skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Infect. Immun., 85. · DOI
- Chan, 2018, Protective immunity in recurrent Staphylococcus aureus infection reflects localized immune signatures and macrophage-conferred memory, Proc. Natl. Acad. Sci. USA, 115, E11111, 10.1073/pnas.1808353115 · DOI
- Leentjens, 2018, Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis, Circ. Res., 122, 664, 10.1161/CIRCRESAHA.117.312465 · DOI
- Maher, 2013, Nlrp-3-driven interleukin 17 production by γδT cells controls infection outcomes during Staphylococcus aureus surgical site infection, Infect. Immun., 81, 4478, 10.1128/IAI.01026-13 · DOI
- Chan, 2015, Nonredundant roles of interleukin-17A (IL-17A) and IL-22 in murine host defense against cutaneous and hematogenous infection due to methicillin-resistant Staphylococcus aureus, Infect. Immun., 83, 4427, 10.1128/IAI.01061-15 · DOI
- Dillen, 2018, Clonally expanded γδ T cells protect against Staphylococcus aureus skin reinfection, J. Clin. Investig., 128, 1026, 10.1172/JCI96481 · DOI
- Clegg, 2021, Staphylococcus aureus vaccine research and development: The past, present and future, including novel therapeutic strategies, Front. Immunol., 12, 705360, 10.3389/fimmu.2021.705360 · DOI · Paper page
- Rappuoli, 2021, Vaccinology in the post−COVID-19 era, Proc. Natl. Acad. Sci. USA, 118, e2020368118, 10.1073/pnas.2020368118 · DOI
- Ford, 2021, Antivirulence strategies for the treatment of Staphylococcus aureus infections: A mini review, Front. Microbiol., 11, 632706, 10.3389/fmicb.2020.632706 · DOI
- Klimka, 2021, Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase, Vaccines, 6, 11
- Bidmos, 2018, Bacterial vaccine antigen discovery in the reverse vaccinology 2.0 era: Progress and challenges, Front. Immunol., 9, 2315, 10.3389/fimmu.2018.02315 · DOI
- Ahmad-Mansour, N., Loubet, P., Pouget, C., Dunyach-Remy, C., Sotto, A., Lavigne, J.-P., and Molle, V. (2021). Staphylococcus aureus toxins: An update on their pathogenic properties and potential treatments. Toxins, 13. · DOI · Paper page
- Micoli, 2021, The role of vaccines in combating antimicrobial resistance, Nature Rev. Microbiol., 19, 287, 10.1038/s41579-020-00506-3 · DOI · Paper page
- Vekemans, 2021, Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: A World Health Organization action framework, Clin. Infect. Dis., 73, e1011, 10.1093/cid/ciab062 · DOI
- Medaglini, 2018, Innovation partnership for a roadmap on vaccines in Europe (IPROVE): A vision for the vaccines of tomorrow, Vaccine, 36, 1136, 10.1016/j.vaccine.2017.11.069 · DOI
- Dijksteel, 2021, Review: Lessons learned from clinical trials using antimicrobial peptides (AMPs), Front. Microbiol., 12, 616979, 10.3389/fmicb.2021.616979 · DOI · Paper page
- Lee, J.-K., and Park, Y. (2020). All d-Lysine analogues of the antimicrobial Peptide HPA3NT3-A2 increased serum stability and without drug resistance. Int. J. Mol. Sci., 21. · DOI
- Ryu, 2014, Colonization and infection of the skin by S. aureus: Immune system evasion and the response to cationic antimicrobial peptides, Int. J. Mol. Sci., 15, 8753, 10.3390/ijms15058753 · DOI
- Speziale, P., and Pietrocola, G. (2021). Monoclonal antibodies targeting surface-exposed and secreted proteins from staphylococci. Vaccines, 9. · DOI
- Swolana, D., Kępa, M., Kabała-Dzik, A., Dzik, R., and Wojtyczka, R.D. (2021). Sensitivity of staphylococcal biofilm to selected compounds of plant origin. Antibiotics, 10. · DOI
- Walsh, 2021, Efficacy of phage- and bacteriocin-based therapies in combating nosocomial MRSA infections, Front. Mol. Biosci., 8, 654038, 10.3389/fmolb.2021.654038 · DOI
Cited by
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Metadata
- Authors
- Wójcik-Bojek, U., Różalska, B., & Sadowska, B.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-01-16
- Volume
- 23
- Issue
- 2
- Pages
- 948
- ISSN
- 1422-0067
- Cited by
- 42
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.